Glycohale Respules (1ml Each) contain Glycopyrrolate 25mcg/ml, an anticholinergic agent used primarily as a bronchodilator in the management of chronic obstructive pulmonary disease (COPD) and other respiratory conditions characterized by bronchospasm. Glycopyrrolate acts by selectively blocking muscarinic receptors in the airway smooth muscle, thereby inhibiting the parasympathetic nervous system’s effect and resulting in bronchodilation. This mechanism helps reduce airway resistance, improve airflow, and alleviate symptoms such as wheezing, shortness of breath, and chronic cough. Glycohale Respules are administered via nebulization, allowing direct delivery to the respiratory tract for rapid onset of action and enhanced therapeutic efficacy. The dosage and duration of treatment should be individualized based on the patient’s clinical response and severity of symptoms. Caution is advised in patients with hypersensitivity to glycopyrrolate or other anticholinergic drugs, glaucoma, prostatic hypertrophy, or bladder neck obstruction. Common side effects may include dry mouth, throat irritation, and occasional dizziness. Glycohale Respules should be used under medical supervision, with monitoring for potential adverse effects and assessment of therapeutic outcomes to ensure optimal management of respiratory conditions.